Evaluation of the Tobacco Heating System 2.2. Part 8: 5-Day randomized reduced exposure clinical study in Poland

Regulatory Toxicology and Pharmacology

Volumn 81, Issue , 2016, Pages S139-S150

  Haziza, Christelle ^a   de La Bourdonnaye, Guillaume ^a   Skiada, Dimitra ^a   Ancerewicz, Jacek ^a   Baker, Gizelle ^a   Picavet, Patrick ^a   Lüdicke, Frank ^a  

^a PHILIP MORRIS PRODUCTS S A   (Switzerland)

Author keywords

Biomarkers of exposure; Conventional cigarettes; Harmful and potentially harmful constituents; Randomized study; Smoking abstinence; Tobacco heating system

Indexed keywords

BIOLOGICAL MARKER; NICOTINE; AEROSOL; CYP1A2 PROTEIN, HUMAN; CYTOCHROME P450 1A2; SMOKE;

ABDOMINAL DISTENSION; ABNORMAL LABORATORY RESULT; ADULT; AGED; ARTICLE; BACKACHE; BLOOD LEVEL; COMBUSTION; CONTROLLED STUDY; DEVICE SAFETY; EQUIPMENT DESIGN; EVALUATION STUDY; EXPOSURE; FAINTNESS; FEMALE; FLU LIKE SYNDROME; GENERAL DEVICE; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INTERMETHOD COMPARISON; MALE; MEDICAL DEVICE COMPLICATION; MODIFIED RISK TOBACCO PRODUCT; NORMAL HUMAN; OPEN STUDY; OROPHARYNX PAIN; PARALLEL DESIGN; POLAND; POLYURIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SATISFACTION; SMOKING CESSATION; SMOKING HABIT; SPIROMETRY; TOBACCO; TREATMENT DURATION; URINE LEVEL; VERTIGO; ADVERSE EFFECTS; AEROSOL; BLOOD; COMPARATIVE STUDY; ELECTRONIC CIGARETTE; HARM REDUCTION; HEAT; METABOLISM; MIDDLE AGED; PREVENTION AND CONTROL; PROCEDURES; PRODUCT SAFETY; RISK ASSESSMENT; SMOKE; SMOKING; TIME FACTOR; TOBACCO INDUSTRY; TOXICITY; TOXICITY TESTING; URINE; YOUNG ADULT;

ADULT; AEROSOLS; BIOMARKERS; CONSUMER PRODUCT SAFETY; CYTOCHROME P-450 CYP1A2; ELECTRONIC CIGARETTES; EQUIPMENT DESIGN; FEMALE; HARM REDUCTION; HOT TEMPERATURE; HUMANS; INHALATION EXPOSURE; MALE; MIDDLE AGED; POLAND; RISK ASSESSMENT; SMOKE; SMOKING; SMOKING CESSATION; TIME FACTORS; TOBACCO INDUSTRY; TOBACCO PRODUCTS; TOXICITY TESTS; YOUNG ADULT;

EID: 85006921186     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2016.11.003     Document Type: Article

References (58)

1. Ames, B.N., et al. Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test. Mutat. Res. 31 (1975), 347–364.
2. Borgerding, M., Klus, H., Analysis of complex mixtures – cigarette smoke. Exp. Toxicol. Pathol. 57 (2005), 43–73.
3. Butler, M.A., et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 2 (1992), 116–127.
4. Cappelleri, J.C., et al. Confirmatory factor analyses and reliability of the modified cigarette evaluation questionnaire. Addict. Behav. 32 (2007), 912–923.
5. Carmella, S.G., et al. Correction to effects of smoking cessation on eight urinary tobacco carcinogen and toxicant biomarkers. Chem. Res. Toxicol., 25, 2012, 763.
6. Cox, L.S., et al. Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings. Nicotine Tob. Res. 3 (2001), 7–16.
7. Einisto, P., et al. Sensitivity of Salmonella typhimurium YG1024 to urine mutagenicity caused by cigarette smoking. Mutat. Res. 245 (1990), 87–92.
8. Euler, D.E., et al. Effect of cigarette smoking on pentane excretion in alveolar breath. Clin. Chem. 42 (1996), 303–308.
9. Faber, M.S., Fuhr, U., Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin. Pharmacol. Ther. 76 (2004), 178–184.
10. Fagerström, K., et al. The Fagerström Test for Nicotine Dependence as a predictor of smoking abstinence: a pooled analysis of varenicline clinical trial data. Nicotine Tob. Res. 14 (2012), 1467–1473.
11. Family Smoking Prevention and Tobacco Control Act. Public Law No. 111–131 (June 22, 2009).
12. FDA (Food and Drug Administration), Guidance for Industry. Analytical Procedures and Methods Validation for Drugs and Biologics. 2001.
13. FDA (Food and Drug Administration), Guidance for Industry - Modified Risk Tobacco Product Applications - Draft Guidance. 2012.
14. FDA (Food and Drug Administration), Guidance for Industry - Reporting Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke under Section 904(a)(3) of the Federal Food, Drug, and Cosmetic Act - Draft Guidance. 2012.
15. Forster, M., et al. An experimental method to study emissions from heated tobacco between 100-200 degrees C. Chem. Cent. J., 9, 2015, 20.
16. Goniewicz, M.L., et al. Elimination kinetics of the tobacco-specific biomarker and lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol. Cancer Epidemiol. Biomark. Prev. 18 (2009), 3421–3425.
17. Gregg, E.O., et al. Urinary biomarkers of smokers' exposure to tobacco smoke constituents in tobacco products assessment: a fit for purpose approach. Biomarkers 18 (2013), 467–486.
18. Gunes, A., Dahl, M.L., Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. Pharmacogenomics 9 (2008), 625–637.
19. Haziza, C., De La, Bourdonnaye, G., Skiada, D., Ancerewicz, J., Baker, G., Picavet, P., Luedicke, F., Evaluation of the Tobacco Heating System 2.2. Part 8: 5-day randomized reduced exposure clinical trial in Poland. Regul. Toxicol. Pharmacol. 81 (2016), S17–S26 (PMID: 27816672).
20. Hecht, S.S., et al. Quantitation of urinary metabolites of a tobacco-specific lung carcinogen after smoking cessation. Cancer Res. 59 (1999), 590–596.
21. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, Chemical agents and related occupations. IARC Monogr. Eval. Carcinog. Risks Hum. 100:Pt F (2012), 9–562.
22. Imbriani, M., et al. [Significance of urinary concentrations of S-benzyl-N-acetylcysteine (S-BMA) in subjects exposed to toluene] Italian. G. Ital. Med. del Lav. Ergon. 21 (1999), 329–333.
23. International Conference on Harmonisation, ICH Harmonised Tripartite Guideline for Good Clinical Practice. 1996 Available from http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf (Accessed on 14 August 2014).
24. IOM (Institute of Medicine), Scientific Standards for Studies on Modified Risk Tobacco Products. 2012, The National Academies Press, Washington, DC.
25. Kogel, U., Titz, B., Schlage, W.K., Nury, C., Martin, F., Oviedo, A., Lebrun, S., Elamin, A., Guedj, E., Trivedi, K., Ivanov, N.V., Vanscheeuwijck, P., Peitsch, M.C., Hoeng, J., Evaluation of the Tobacco Heating System 2.2. Part 7: systems toxicological assessment of a mentholated version revealed reduced cellular and molecular exposure effects compared with cigarette smoke. Regul. Toxicol. Pharmacol. 81 (2016), S123–S138 (PMID: 27818347).
26. Kroon, L.A., Drug interactions with smoking. Am. J. Health Syst. Pharm. 64 (2007), 1917–1921.
27. Lo Sasso, G., et al. Effects of cigarette smoke, cessation and switching to a candidate modified risk tobacco product on the liver in Apoe(-/-) mice - a systems toxicology analysis. Inhal. Toxicol. 28 (2016), 226–240.
28. Lovreglio, P., et al. Validity of new biomarkers of internal dose for use in the biological monitoring of occupational and environmental exposure to low concentrations of benzene and toluene. Int. Arch. Occup. Environ. Health 83 (2010), 341–356.
29. Lüdicke, F., et al. Reduced exposure to harmful and potentially harmful smoke constituents with the tobacco heating system 2.1. Nicotine Tob. Res., 2016.
30. MacLeod, S., et al. Polymorphisms of CYP1A1 and GSTM1 influence the in vivo function of CYP1A2. Mutat. Res. 376 (1997), 135–142.
31. Martin, F., Ivanov, N.V., Haziza, C., Hoeng, J., Peitsch, M.C., Evaluation of the Tobacco Heating System 2.2. Part 9: application of systems pharmacology to identify exposure response markers in peripheral blood of smokers switching to THS2.2. Regul. Toxicol. Pharmacol. 81 (2016), S151–S157 (PMID: 27845159).
32. Matsuda, K., et al. 2015 Genome-wide association study identified SNP on 15q24 associated with bladder cancer risk in Japanese population. Hum. Mol. Genet. 24 (2015), 1177–1184.
33. Miura, N., et al. A study to investigate changes in the levels of biomarkers of exposure to selected cigarette smoke constituents in Japanese adult male smokers who switched to a non-combustion inhaler type of tobacco product. Regul. Toxicol. Pharmacol. 71 (2015), 498–506.
34. OECD (Organization for Economic Co-operation and Development), Guidelines for the Testing of Chemicals: Bacterial Reverse Mutation Test [test 471]. 1997 Available from http://www.oecd.org/chemicalsafety/risk-assessment/1948418.pdf (Accessed on 13 January 2016).
35. OECD (Organization for Economic Co-operation and Development), SIDS Initial Assessment Report for SIAM 20: Isoprene., 2005 Available from http://webnet.oecd.org/HPV/UI/handler.axd?id2d19a70d-10ec-4ff9-9b9a-0978d0db8798 (Accessed on 24 June 2016).
36. Oviedo, A., Lebrun, S., Kogel, U., Ho, J., Tan, W.T., Titz, B., Leroy, P., Vuillaume, G., Bera, M., Martin, F.T., Rodrigo, G., Esposito, M., Dempsey, R., Ivanov, N.V., Hoeng, J., Peitsch, M.C., Vanscheeuwijck, P., Evaluation of the Tobacco Heating System 2.2. Part 6: 90-day rat inhalation study with systems toxicology endpoints demonstrates reduced exposure effects of a mentholated version compared with cigarette smoke. Regul. Toxicol. Pharmacol. 81 (2016), S93–S122 (PMID: 27818348).
37. Qadariyah, L., et al. Degradation of glycerol using hydrothermal process. Bioresour. Technol. 102 (2011), 9267–9271.
38. Rodgman, A., Perfetti, T.A., The Chemical Components of Tobacco and Tobacco Smoke. 2013, CRC Press, Taylor & Francis Inc, United States.
39. Roethig, H.J., et al. A 12-month, randomized, controlled study to evaluate exposure and cardiovascular risk factors in adult smokers switching from conventional cigarettes to a second-generation Electrically Heated Cigarette Smoking System. J. Clin. Pharmacol. 48 (2008), 580–591.
40. Roethig, H.J., et al. Short term effects of reduced exposure to cigarette smoke on white blood cells, platelets and red blood cells in adult cigarette smokers. Regul. Toxicol. Pharmacol. 57 (2010), 333–337.
41. Royal College of Physicians, Nicotine without Smoke. Tobacco Harm Reduction. A Report by the Tobacco Advisory Group of the Royal College of Physicians., 2016, RCP, London.
42. Sakaguchi, C., et al. Exposure evaluation of adult male Japanese smokers switched to a heated cigarette in a controlled clinical setting. Regul. Toxicol. Pharmacol. 69 (2014), 338–347.
43. Sarkar, M., et al. Evaluation of biomarkers of exposure to selected cigarette smoke constituents in adult smokers switched to carbon-filtered cigarettes in short-term and long-term clinical studies. Nicotine Tob. Res. 10 (2008), 1761–1772.
44. Sarkar, M., et al. Valuation of biomarkers of exposure in adult cigarette smokers using Marlboro snus. Nicotine Tob. Res. 12 (2010), 105–116.
45. Schaller, J.-P., et al. Evaluation of the Tobacco Heating System 2.2. Part 2: Chemical Composition, Genotoxicity, Cytotoxicity, and Physical Properties of the Aerosol, 81, 2016, S27–S47.
46. Schaller, J.-P., Pijnenburg, J.P.M., Ajithkumar, A., Tricker, A.R., Evaluation of the Tobacco Heating System 2.2. Part 3: influence of the tobacco blend on the formation of harmful and potentially harmful constituents of the Tobacco Heating Systems 2.2 aerosol. Regul. Toxicol. Pharmacol. 81 (2016), S48–S58 (PMID: 27793747).
47. Schettgen, T., et al. Fast determination of urinary S-phenylmercapturic acid (S-PMA) and S-benzylmercapturic acid (S-BMA) by column-switching liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 863 (2008), 283–292.
48. Sewer, A., Kogel, U., Talikka, M., Wong, E., Guedj, E., Ivanov, N.V., Hoeng, J., Peitsch, M.C., Evaluation of the Tobacco Heating System 2.2. Part 5: miRNA expression from a 90-day rat inhalation study indicates reduced effects of the aerosol on lung tissue compared with cigarette smoke exposure. Regul. Toxicol. Pharmacol., 2016 (accepted).
49. Smith, M., et al. Evaluation of the Tobacco Heating System 2.2. Part 1 Description of the System and the Scientific Assessment Program, 81, 2016, S17–S26.
50. Theophilus, E.H., et al. Magnitudes of biomarker reductions in response to controlled reductions in cigarettes smoked per day: a one-week clinical confinement study. Reg. Tox. Pharm. 71 (2015), 225–234.
51. U.S. Department of Health and Human Services, Docket No. FDA-2012-N-0143: harmful and potentially harmful constituents in tobacco products and tobacco smoke; established list. Fed. Regist. 77 (2012), 20034–20037.
52. U.S. Department of Health and Human Services, The Health Consequences of Smoking - 50 Years of Progress: a Report of the Surgeon General., 2014.
53. U.S. Department of Health and Human Services, et al. Toxicological Profile for Ethylene Oxide. 1990 Available from http://www.atsdr.cdc.gov/toxprofiles/tp137.pdf (Accessed on 27 January 2015).
54. Unverdorben, M., et al. Acute effects of cigarette smoking on pulmonary function. Regul. Toxicol. Pharmacol. 57 (2010), 241–246.
55. Uppsala Monitoring Centre, WHO Drug Dictionary Enhanced (WHO DDE). 2012 Available from www.umc-products.com (Accessed on 03 November 2014).
56. WHO Study Group, et al. The scientific basis of tobacco product regulation: second report of a WHO study group. World Health Organ Tech. Rep. Ser. 1–277 (2008), 1–277.
57. Wong, E., Kogel, U., Veljkovic, E., Martin, F., Xiang, Y., Boue, S., Vuillaume, G., Leroy, P., Guedj, E., Rodrigo, G., Ivanov, N.V., Hoeng, J., Peitsch, M.C., Vanscheeuwijck, P., Evaluation of the Tobacco Heating System 2.2. Part 4: 90-day OECD 413 rat inhalation study with systems toxicology endpoints demonstrates reduced exposure effects compared with cigarettes smoke. Regul. Toxicol. Pharmacol., 81, 2016 pp. S59–S81 (PMID: 27793746).
58. World Medical Association (WMA), WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects. 2013.